CAR T-cell
Advertisement
A study presented at the 2022 American Society of Clinical Oncology Annual Meeting found that an autologous CD7 chimeric ...
The approach may help inform clinical decision-making early in treatment.
Chimeric antigen receptor (CAR) T-cell therapy is a promising new treatment option for certain oncology patient ...
Background aims: Efforts to safely and effectively treat acute myeloid leukemia (AML) by targeting a single ...
The chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel (axi-cel) demonstrated significant and ...
Noopur Raje, MD, Director of the Multiple Myeloma Program at Massachusetts General Hospital, looks into the future of ...
Noopur Raje, MD, Director of the Multiple Myeloma Program at Massachusetts General Hospital, describes the new ...
Pivotal trials that supported Food and Drug Administration (FDA) approval of chimeric antigen receptor (CAR) T-cell ...
In a single-arm phase I/II study, infusion with CT103A, a novel fully human B-cell maturation antigen (BCMA)-targeted ...
Chimeric antigen receptor (CAR) T-cell therapy is a potentially life-saving option for patients with hematologic ...
This week on DocWire, we covered the latest breaking research from the American Society of Hematology (ASH) 2021 Annual ...
Pivotal trials that supported Food and Drug Administration (FDA) approval of chimeric antigen receptor (CAR) T-cell ...
Black Americans were severely under-represented in clinical trials that supported FDA approvals of chimeric antigen ...
Patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma (NHL) who received second-line treatment with ...
A study reported updated results from the CARTITUDE-1 trial, which previously showed that cilacabtagene autoleucel ...
Prescribing chemotherapy is not a universal practice of advanced practice providers (APPs) in the oncology community, ...
According to new research presented during the 2021 ASH Annual Meeting, circulating tumor DNA (ctDNA) accurately ...
Chimeric antigen receptor (CAR) T-cell therapy with lisocabtagene maraleucel (liso-cel) significantly improved ...
Despite advances in novel therapies, survival rates remain poor for patients with relapsed/refractory aggressive B-cell ...
Greetings, DocWire News readers. I attempt here to summarize the most important updates from the 2021 International ...
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.